Importance Approval by the US Food and Drug Administration of immune checkpoint
inhibition (ICI) for advanced gastroesophageal cancer (aGEC) irrespective of PD-L1 status …

Purpose This study aimed to clarify the current knowledge on the use of immunotherapy in
patients with advanced gastric (G)/gastroesophageal (GEJ) cancers. Materials and methods …

Simple Summary Gastric cancer is one of the most common malignant tumours worldwide,
with the fifth and third highest morbidity and mortality, respectively, of all cancers. Survival is …

Gastrointestinal (GI) cancers, including esophageal, gastroesophageal junction, gastric,
duodenal and distal small bowel, biliary tract, pancreatic, colon, rectal, and anal cancer …

Immune checkpoint inhibition (ICI) is an established therapeutic option for patients with
deficient mismatch repair or high levels of microsatellite instability tumors. Yet, response to …

Recent data support incorporation of immune checkpoint inhibitors into the treatment
armamentarium for esophageal, gastroesophageal junction, and gastric (esophagogastric) …

Although phase III trials have reported improved overall survival in patients with advanced
esophageal squamous cell carcinoma following treatment with nivolumab, as compared with …

Background Tumors in the distal esophagus (EAC), gastro-esophageal junction including
cardia (GEJAC), and stomach (GAC) develop in close proximity and show strong similarities …

Colorectal cancer (CRC) represents a global health threat, standing as the second leading
cause of cancer-related death worldwide. Targeted therapies brought new hope for the …

Introduction Gastric cancer has the highest incidence and mortality in Eastern Asia. The
efficacy and safety of ramucirumab (RAM) monotherapy or in combination with paclitaxel …